Abstract：Objective To investigate the level and clinical significance of plasma endothelin-1 (ET-1) and platelet pselectin (CD62P) in patients with chronic obstructive pulmonary disease (COPD).Methods A total of 68 patients with acute exacerbation of COPD (AECOPD) in our hospital from June 2017 to September 2018 were selected as group A,79 patients with stable COPD who were reviewed in the same clinic were selected as the group B, and a total of 72 healthy examinees served as the healthy control group C.The plasma ET-1 and platelet surface CD62P levels of the three groups were detected and compared, and the relationship between the plasma ET-1, platelet surface CD62P levels and arterial blood oxygen partial pressure (PaO2), arterial blood carbon dioxide partial pressure (PaCO2) was analyzed in group A and B.Results The plasma ET-1 and platelet CD62P levels in group A were higher than those in group B and C, and the differences were statistically significant (P＜0.05).There were no significant differences in the levels of plasma ET-1 and platelet CD62P between group B and group C (P＞0.05).There were no significant differences in PaO2 and PaCO2 between group A and group B (P＞0.05).Plasma ET-1 and platelet CD62P levels were negatively correlated with PaO2 (r=-0.41, -0.43, P＜0.05), and positively correlated with PaCO2 (r=0.56, 0.58, P＜0.05).Conclusion The detection of ET-1 and CD62P in COPD patients is helpful for the early detection and clinical intervention of prethrombotic state (PTS) in COPD patients.
Grouse L，Nonikov D.The global battle to improve patients′health outcomes：COPD awareness，activities，and progress[J].J Thorac Dis，2014，6（2）：161-168.
[2]
Polatli M，Ben Kheder A，Wali S，et al.Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa：the BREATHE study[J].Respir Med，2013，106 Suppl 2：S75-S85.
Takahashi T.Annual FEV1 changes and numbers of circulating endothelial microparticles in patients with COPD：a prospective study[J].BMJ Open，2014，4（3）：4571-4572.
[5]
Leuppi JD，Schuetz P，Bingisser R，et al.Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease：the REDUCE randomized clinical trial[J].JAMA，2013，309（21）：2223-2231.
Demeyer H.Standardizing the analysis of physical activity in patients with COPD following a pulmonary rehabilitation program[J].Chest，2014，6（10）：1965-1968.
[8]
薛建峰，赵成军，贾如意.血管内皮损伤标志物[J].医学综述，2006，12（8）：461-463.
[9]
Clark NP，Delate T，Riggs CS，et al.Warfarin Interactions With Antibiotics in the Ambulatory Care Setting[J].JAMA Intern Med，2014，174（3）：409-416.
[10]
Niewiada M，Czlonkowka A.Prevention of ischemic stroke in clinical practice：a role of internists and general practitioners[J].Pol Arch Med Wewn，2014，124（10）：540-548.
[11]
Lee JH，Chun YG，Lee IC，et al.Pathogenic role of endothelin 1 in hemodynamic dysfunction in experimental acute pulmonary thromboembolism[J].Am J Respir Crit Care Med，2001，164（7）：1282-1287.
[12]
Raskob G，Wendelboe AM.Global public awareness of venous thromboembolism：reply[J].J Thromb Haemost，2016，14（5）：1111-1112.
[13]
Tanus-Santos JE，Gordo WM，Udelsmann A，et al.Nonselective endothelin-receptor antagonism attenuates hemodynamic changes after massive pulmonary air embolism in dogs[J].Chest，2000，118（1）：175-179.
[14]
Rios L，Fuentes HE，Oramas DM，et al.Validation of a Patient-Completed Caprini Risk Assessment Tool for Spanish，Arabic，and Polish Speakers[J].Clin Appl Thromb Haemost，2018，24（3）：502-512.
[18]
Heit JA.Epidemiology of venous thromboembolism[J].Nat Rev Cardiol，2015，12（8）：464-474.
[15]
Saraiva C，Abreu T，Neves D，et al.Mortality predictive factors in subjects with COPD after a pulmonary rehabilitation program：a 3-year study[J].Respir Care，2016，61（9）：1179-1185.
[16]
Ferroni P，Basili S，Martini F，et al.Soluble P-selectin as a marker of platelet hyperactivity in patients with chronic obstructive pulmonary disease[J].J Investig Med，2000，48（1）：21-27.
[17]
Khare P，Talwar A，Chandran D，et al.Impaired systemic vascular reactivity & raised high-sensitivity C reactive protein levels in chronic obstructive pulmonary disease[J].Indian J Med Res，2016，143（2）：205-212.
[19]
Schumacher A，Liebers U，John M，et al.P-selectin glycoprotein ligand-1（PSGL-1）is up-regulated on leucocytes from patients with chronic obstructive pulmonary disease[J].Clin Exp Immunol，2005，142（2）：370-376.
[20]
Harrison MT，Short P，Williamson PA，et al.Thrombocytosis is associated with increased short and long term mortality after exacerbation of chronic obstructive pulmonary disease：a role for antiplatelet therapy[J].Thorax，2014，69（7）：609-615.
[21]
Sin DD.The devastating power of platelets in COPD exacerbations：can aspirin save lives in COPD[J].Thorax，2014，69（7）：603-604.
京公网安备 11010502046607号